---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-011868"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2023-07-13T23:59:59+00:00"
generated_at: "2026-06-13T08:33:45.010595+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Protalix BioTherapeutics shareholders approve increase in authorized common shares from 144M to 185M

## Summary
- Amendment to Certificate of Incorporation approved at reconvened 2023 Annual Meeting on July 13, 2023.
- Authorized common shares increased by 41M, from 144M to 185M.
- Votes: 33,870,055 for, 9,479,063 against, 1,042,433 abstentions.
- Proposal passed with approximately 76% of votes cast in favor.

## SEC filing metadata
- accession: 0001558370-23-011868
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2023-07-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837023011868/0001558370-23-011868-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837023011868/plx-20230713x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-011868
- JSON: https://secwatch.observer/filing/0001558370-23-011868.json
- Plain text: https://secwatch.observer/filing/0001558370-23-011868.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.